Asthma (Moderate to Severe), Adjunct: For patients aged 6 years and older with an eosinophilic phenotype or those dependent on oral corticosteroids.
中重度哮喘的輔助治療：適用於6歲及以上具有嗜伊紅性表型或依賴口服皮質類固醇的患者。

Atopic Dermatitis (Moderate to Severe): For patients aged 6 months and older not adequately controlled with topical therapies or when those therapies are inadvisable.
中重度異位性皮膚炎：適用於6個月及以上局部療法控制不佳或不適合使用局部療法的患者。

Nasal Polyps - Chronic Sinusitis, Adjunct、Nodular Prurigo、Eosinophilic Esophagitis (EoE)
慢性鼻竇炎伴鼻息肉的輔助治療、結節性癢疹、嗜伊紅性食道炎 (EoE) <20241225>

Dupilumab is a human monoclonal IgG4 antibody that inhibits interleukin-4 and interleukin-13 cytokine-induced responses, including release of proinflammatory cytokines, chemokines, and IgE

AbsorptionTmax, subQ: 1 week Bioavailability, subQ: 60.7% to 64%DistributionVd: 4.8 L Vd: 2.74 L (central), 1.38 L (peripheral)

Known hypersensitivity to dupilumab or any component of the formulation

Dupilumab is a monoclonal IgG antibody; IgG molecules are known to cross the placenta therefore exposure to the fetus during pregnancy may occur. Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of preeclampsia, preterm birth, low birth weight infants). Asthma should be closely monitored in pregnant women.

It is not known if dupilumab is present in breast milk; however, maternal IgG molecules are present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.

CommonDermatologic: Injection site reaction (6% to 18% )Gastrointestinal: Dental pain (2% ), Oral herpes simplex infection (3% to 4% )Immunologic: Herpes simplex, Excluding oral and ophthalmic herpes simplex (1% to 2% )Ophthalmic: Blepharitis (Up to 5% ), Conjunctivitis (Atopic dermatitis, 9% to 16% ; chronic rhinosinusitis with nasal polyposis, 2% ), Dry eyes (Up to 2% ), Itching of eye (1% to 2% ), Keratitis (Atopic dermatitis, up to 4% )SeriousCardiovascular: Arterial thromboembolism (0% to 0.9% ), VasculitisHematologic: Eosinophil count raised (1% to 2% )Respiratory: Pneumonia, Eosinophilic

"Asthma, moderate to severe: SubQ:Initial: 400 mg (given as two 200 mg injections) or 600 mg (given as two 300 mg injections).Maintenance: 200 mg (following 400 mg initial dose) or 300 mg (following 600 mg initial dose) once every other week.Asthma, oral corticosteroid dependent or with comorbid moderate to severe atopic dermatitis: SubQ:Initial: 600 mg (given as two 300 mg injections).Maintenance: 300 mg once every other week.Atopic dermatitis: SubQ:Initial: 600 mg (given as two 300 mg injections).Maintenance: 300 mg once every other week.Rhinosinusitis (chronic) with nasal polyposis: SubQ: 300 mg once every other week."

Store in original carton under refrigeration between 2 and 8 degrees C; protect from heat or direct sunlight. Do not freeze or shake.